Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF.

Blood Adv. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922.

PMID:
31738830
2.

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M.

Sci Transl Med. 2019 Jul 10;11(500). pii: eaav5467. doi: 10.1126/scitranslmed.aav5467.

PMID:
31292266
3.

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E.

Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20.

PMID:
31111177
4.

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jun;104(6):1230-1236. doi: 10.3324/haematol.2018.201400. Epub 2019 Jan 17.

5.

LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.

Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G.

Leukemia. 2019 Jun;33(6):1501-1513. doi: 10.1038/s41375-018-0336-1. Epub 2019 Jan 3.

PMID:
30607021
6.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

7.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

8.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
9.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. No abstract available.

PMID:
29963936
10.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. No abstract available.

11.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

12.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

13.

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. No abstract available.

14.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R.

Oncotarget. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10.

15.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
16.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A.

Haematologica. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5.

17.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.

J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.

PMID:
28605290
18.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T.

Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.

19.

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD.

Oncotarget. 2017 Jun 6;8(23):37866-37874. doi: 10.18632/oncotarget.15200.

20.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
21.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.

22.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

23.

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.

Sallman DA, Cluzeau T, Basiorka AA, List A.

Front Oncol. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Review.

24.

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.

Dubois A, Ginet C, Furstoss N, Belaid A, Hamouda MA, El Manaa W, Cluzeau T, Marchetti S, Ricci JE, Jacquel A, Luciano F, Driowya M, Benhida R, Auberger P, Robert G.

Oncotarget. 2016 May 3;7(18):26120-36. doi: 10.18632/oncotarget.8319.

25.

Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, Devys A, De Matteis M, Dubois V, Filloux M, Fort M, Hau F, Jollet I, Labalette M, Masson D, Mercier B, Pedron B, Perrier P, Picard C, Quainon F, Ramounau-Pigot A, Renac V, Van Endert P, Charron D, Peffault de la Tour R, Taupin JL, Loiseau P.

Bone Marrow Transplant. 2016 May;51(5):687-91. doi: 10.1038/bmt.2015.351. Epub 2016 Feb 8.

PMID:
26855158
26.

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E.

Leukemia. 2016 Mar;30(3):666-73. doi: 10.1038/leu.2015.304. Epub 2015 Oct 30.

PMID:
26514544
27.

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.

McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF.

Oncotarget. 2015 Oct 27;6(33):34437-45. doi: 10.18632/oncotarget.5255.

28.

[Management of myelodysplastic syndromes].

Duchmann M, Fenaux P, Cluzeau T.

Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26. Review. French.

PMID:
26410692
29.

Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.

Segot A, Raffoux E, Lengline E, Thieblemont C, Dombret H, Boissel N, Cluzeau T.

Ann Hematol. 2015 Nov;94(11):1859-63. doi: 10.1007/s00277-015-2475-z. Epub 2015 Aug 18.

PMID:
26280395
30.

Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.

Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti AM, Sebert M, Boissel N, Robin M, Vey N, Kiladjian JJ, Dombret H, Cluzeau T.

Br J Haematol. 2016 Feb;172(4):628-30. doi: 10.1111/bjh.13516. Epub 2015 Jun 10. No abstract available.

PMID:
26061174
31.

The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML.

Obba S, Hizir Z, Boyer L, Selimoglu-Buet D, Pfeifer A, Michel G, Hamouda MA, Gonçalvès D, Cerezo M, Marchetti S, Rocchi S, Droin N, Cluzeau T, Robert G, Luciano F, Robaye B, Foretz M, Viollet B, Legros L, Solary E, Auberger P, Jacquel A.

Autophagy. 2015;11(7):1114-29. doi: 10.1080/15548627.2015.1034406.

32.

Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.

Cluzeau T, Lippert E, Cayuela JM, Maarek O, Migeon M, Noguera ME, Dombret H, Rea D.

Eur J Haematol. 2015 Nov;95(5):480-3. doi: 10.1111/ejh.12576. Epub 2015 May 20.

PMID:
25941032
33.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C.

Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.

PMID:
25524177
34.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N.

Blood. 2014 Aug 21;124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8.

PMID:
25006122
35.

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.

Cluzeau T, Dubois A, Jacquel A, Luciano F, Renneville A, Preudhomme C, Karsenti JM, Mounier N, Rohrlich P, Raynaud S, Mari B, Robert G, Auberger P.

Oncotarget. 2014 Jun 30;5(12):4384-91.

36.

Pediatric-like therapy for adults with ALL.

Dombret H, Cluzeau T, Huguet F, Boissel N.

Curr Hematol Malig Rep. 2014 Jun;9(2):158-64. doi: 10.1007/s11899-014-0210-9. Review.

PMID:
24682859
37.

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E.

Haematologica. 2014 Jul;99(7):1197-203. doi: 10.3324/haematol.2014.104075. Epub 2014 Mar 21.

38.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

39.

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.

Cluzeau T, Moreilhon C, Mounier N, Karsenti JM, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Auberger P, Fuzibet JG, Cassuto JP, Raynaud S.

Blood Cancer J. 2013 Nov 1;3:e155. doi: 10.1038/bcj.2013.52.

40.

Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.

Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP.

Am J Hematol. 2013 Sep;88(9):780-3. doi: 10.1002/ajh.23509. Epub 2013 Jul 23.

41.

How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.

Cluzeau T, Robert G, Jacquel A, Auberger P.

Curr Pharm Des. 2013;19(30):5362-73. Review.

PMID:
23394086
42.

[New tools and treatments in myelodysplastic syndromes].

Cluzeau T, Fenaux P.

Rev Med Interne. 2013 Mar;34(3):159-67. doi: 10.1016/j.revmed.2012.06.009. Epub 2012 Jul 4. Review. French.

PMID:
22766158
43.

BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P.

Oncotarget. 2012 Apr;3(4):490-501.

44.

The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production.

Robert G, Puissant A, Dufies M, Marchetti S, Jacquel A, Cluzeau T, Colosetti P, Belhacene N, Kahle P, Da Costa CA, Luciano F, Checler F, Auberger P.

Cell Death Differ. 2012 Nov;19(11):1769-78. doi: 10.1038/cdd.2012.55. Epub 2012 May 4.

45.

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P.

J Mol Cell Biol. 2012 Aug;4(4):207-20. doi: 10.1093/jmcb/mjs010. Epub 2012 Mar 31.

PMID:
22467682
46.

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.

Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P.

Oncotarget. 2011 Nov;2(11):874-85.

47.

Mechanism of action of the multikinase inhibitor Foretinib.

Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N, Legros L, Raynaud S, Cassuto JP, Luciano F, Auberger P.

Cell Cycle. 2011 Dec 1;10(23):4138-48. doi: 10.4161/cc.10.23.18323. Epub 2011 Dec 1.

PMID:
22101270
48.

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.

Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.

Cell Cycle. 2011 Jul 15;10(14):2323-30. Epub 2011 Jul 15.

PMID:
21654193
49.

Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy.

Cluzeau T, Robert G, Puissant A, Jean-Michel K, Cassuto JP, Raynaud S, Auberger P.

Cell Cycle. 2011 Jul 15;10(14):2339-43. Epub 2011 Jul 15.

PMID:
21654192
50.

New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.

Cluzeau T, De Matteis M, Mounier N, Mannone L, Gratecos N, Ticchioni M, Thyss A, Raynaud S, Cassuto JP, Sirvent A.

Am J Hematol. 2011 Jul;86(7):619-21. doi: 10.1002/ajh.22029. Epub 2011 Apr 20. No abstract available.

Supplemental Content

Loading ...
Support Center